MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Celldex Therapeutics Operating Income 2011-2026 | CLDX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Celldex Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -195 M | -155 M | -115 M | -71.2 M | -63.4 M | -55 M | -156 M | -122 M | -133 M | -130 M | -122 M | -81.4 M | -58.1 M | -43.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -43.4 M | -195 M | -107 M |
Quarterly Operating Income Celldex Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -73.6 M | -63.9 M | -62.7 M | - | -52.1 M | -46.3 M | -40.6 M | - | -41.2 M | -33.2 M | -32.5 M | - | -27.7 M | -36.4 M | -23.3 M | - | -20.8 M | -13.4 M | -16.6 M | - | -14.3 M | -11.4 M | -12.9 M | - | -11.8 M | -12.3 M | -17.9 M | - | -7.76 M | -16.9 M | -120 M | - | -32 M | -28.9 M | -35.1 M | - | -30 M | -32.4 M | -35.7 M | - | -32.4 M | -32.8 M | -31 M | - | -30.3 M | -28.5 M | -31.5 M | - | -23.3 M | -18.7 M | -17.4 M | - | -14.8 M | -13.5 M | -13.3 M | - | -11.5 M | -9.88 M | -9.66 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.76 M | -120 M | -29.4 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biogen
BIIB
|
7.04 B | $ 172.65 | 0.62 % | $ 25.1 B |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-36 M | $ 2.38 | -4.22 % | $ 134 M |  China |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 117.22 | 1.07 % | $ 27.2 B | Germany |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 12.1 | -5.47 % | $ 797 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-67.2 M | $ 1.78 | -2.47 % | $ 4.51 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-24.8 M | $ 3.05 | -1.77 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 232.9 | -1.06 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.73 | -0.21 % | $ 1.57 B | Britain |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Cellectis S.A.
CLLS
|
-131 M | $ 4.21 | -4.84 % | $ 116 M | France |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
98.3 M | $ 67.14 | 0.13 % | $ 8.98 B | USA |
 |
Compugen Ltd.
CGEN
|
-14.9 M | $ 2.05 | -1.91 % | $ 184 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 4.4 | -2.87 % | $ 9.57 B | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 26.56 | 2.45 % | $ 1.29 B | USA |
 |
Coherus BioSciences
CHRS
|
-203 M | $ 2.25 | 9.22 % | $ 212 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
249 M | $ 13.58 | 1.42 % | $ 4.2 B | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.75 | 1.84 % | $ 17.3 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 94.2 | 1.34 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |